Contribution: Industrial Research Assistance Program – Contributions to Firms
Kane Biotech Inc.
$75,000.00
MNC Collab - DispersinB Wound Gel - DispersinB Wound Gel Development and Commercialization
EF 2024-25 · 2024-09-02
Résumé
As part of Multinational Corporate Collaboration Program, the project “DispersinB Wound Gel Development and Commercialization” will focus on scaling up the manufacturing process for DispersinB Wound Gel and ensuring the product meets specifications. The DispersinB Wound Gel is a combination product (device, drug, biologic) that is first of its kind in wound care as it disperses biofilms enzymatically.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Winnipeg|Winnipeg, Manitoba, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
884326117
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2025-02-21
Agreement Number
1022709
Agreement Start Date
2024-09-02
Agreement Title
MNC Collab - DispersinB Wound Gel - DispersinB Wound Gel Development and Commercialization
Agreement Title (French)
MNC Collab - DispersinB Wound Gel - Développement et commercialisation du DispersinB (gel pour les plaies)
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
As part of Multinational Corporate Collaboration Program, the project “DispersinB Wound Gel Development and Commercialization” will focus on scaling up the manufacturing process for DispersinB Wound Gel and ensuring the product meets specifications. The DispersinB Wound Gel is a combination product (device, drug, biologic) that is first of its kind in wound care as it disperses biofilms enzymatically.
Description (French)
Dans le cadre du programme de collaboration entre entreprises multinationales, le projet « DispersinB Wound Gel Development and Commercialization » (développement et commercialisation du gel DispersinB pour les plaies) se concentrera sur l’augmentation du processus de fabrication du gel DispersinB pour les plaies et sur la conformité du produit aux spécifications. Le DispersinB Wound Gel est un produit combiné (dispositif, médicament, produit biologique) qui est le premier de son genre dans le domaine du traitement des plaies, car il disperse les biofilms par voie enzymatique.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Winnipeg South
Federal Riding (French)
Winnipeg-Sud
Federal Riding Number
46013
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
884326117
Recipient City
Winnipeg|Winnipeg
Recipient Country
CA
Recipient Legal Name
Kane Biotech Inc.
Recipient Postal Code
R3T 6G2
Recipient Province or Territory
MB
Recipient Type
F
Reference Number
172-2024-2025-Q2-1022709
